411 related articles for article (PubMed ID: 24736023)
1. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
2. Niclosamide Analogs for Treatment of Ovarian Cancer.
Walters Haygood CL; Arend RC; Gangrade A; Chettiar S; Regan N; Hassmann CJ; Li PK; Hidalgo B; Straughn JM; Buchsbaum DJ
Int J Gynecol Cancer; 2015 Oct; 25(8):1377-85. PubMed ID: 26186072
[TBL] [Abstract][Full Text] [Related]
3. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
4. Effect of niclosamide on basal-like breast cancers.
Londoño-Joshi AI; Arend RC; Aristizabal L; Lu W; Samant RS; Metge BJ; Hidalgo B; Grizzle WE; Conner M; Forero-Torres A; Lobuglio AF; Li Y; Buchsbaum DJ
Mol Cancer Ther; 2014 Apr; 13(4):800-11. PubMed ID: 24552774
[TBL] [Abstract][Full Text] [Related]
5. MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/β-catenin signaling pathway.
Wu G; Liu A; Zhu J; Lei F; Wu S; Zhang X; Ye L; Cao L; He S
Oncotarget; 2015 Oct; 6(30):28882-94. PubMed ID: 26337084
[TBL] [Abstract][Full Text] [Related]
6. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
Arend RC; Londoño-Joshi AI; Gangrade A; Katre AA; Kurpad C; Li Y; Samant RS; Li PK; Landen CN; Yang ES; Hidalgo B; Alvarez RD; Straughn JM; Forero A; Buchsbaum DJ
Oncotarget; 2016 Dec; 7(52):86803-86815. PubMed ID: 27888804
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
Boone JD; Arend RC; Johnston BE; Cooper SJ; Gilchrist SA; Oelschlager DK; Grizzle WE; McGwin G; Gangrade A; Straughn JM; Buchsbaum DJ
Lab Invest; 2016 Feb; 96(2):249-59. PubMed ID: 26658453
[TBL] [Abstract][Full Text] [Related]
8. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
Wang LH; Xu M; Fu LQ; Chen XY; Yang F
Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
[TBL] [Abstract][Full Text] [Related]
9. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
[TBL] [Abstract][Full Text] [Related]
10. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
11. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
Zhang C; Zhang Z; Zhang S; Wang W; Hu P
Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
[TBL] [Abstract][Full Text] [Related]
13. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway.
Shan BE; Wang MX; Li RQ
Cancer Invest; 2009 Jul; 27(6):604-12. PubMed ID: 19440933
[TBL] [Abstract][Full Text] [Related]
14. WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.
King ML; Lindberg ME; Stodden GR; Okuda H; Ebers SD; Johnson A; Montag A; Lengyel E; MacLean Ii JA; Hayashi K
Oncogene; 2015 Jun; 34(26):3452-62. PubMed ID: 25174399
[TBL] [Abstract][Full Text] [Related]
15. Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells.
Yu S; Wang Z; Su Z; Song J; Zhou L; Sun Q; Liu S; Li S; Li Y; Wang M; Zhang GQ; Zhang X; Liu ZJ; Lu D
BMC Complement Altern Med; 2018 Feb; 18(1):59. PubMed ID: 29444668
[TBL] [Abstract][Full Text] [Related]
16. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.
Barghout SH; Zepeda N; Xu Z; Steed H; Lee CH; Fu Y
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):173-8. PubMed ID: 26522223
[TBL] [Abstract][Full Text] [Related]
17. Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer.
Kaltofen T; Preinfalk V; Schwertler S; Fraungruber P; Heidegger H; Vilsmaier T; Vattai A; Czogalla B; Mayr D; Mahner S; Jeschke U; Trillsch F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2559-2574. PubMed ID: 32681294
[TBL] [Abstract][Full Text] [Related]
18. Effective and new potent drug combination: Histone deacetylase and Wnt/β-catenin pathway inhibitors in lung carcinoma cells.
Akgun O; Erkisa M; Ari F
J Cell Biochem; 2019 Sep; 120(9):15467-15482. PubMed ID: 31037769
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of ovarian tumor-initiating cells by niclosamide.
Yo YT; Lin YW; Wang YC; Balch C; Huang RL; Chan MW; Sytwu HK; Chen CK; Chang CC; Nephew KP; Huang T; Yu MH; Lai HC
Mol Cancer Ther; 2012 Aug; 11(8):1703-12. PubMed ID: 22576131
[TBL] [Abstract][Full Text] [Related]
20. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]